Subject:
All Disciplines Arts & Humanities Biology & Life Sciences Business & Economics Chemistry & Materials Science Computer Science & Mathematics Engineering Environmental & Earth Sciences Medicine & Pharmacology Physical Sciences Public Health & Healthcare Social Sciences
Sort:
Hottest Latest Alphabetical (A-Z) Alphabetical (Z-A)
Type:
All Topic Review Biography
Topic Review
Vasospasm in Fluoropyrimidine-Induced Ischemic Heart Disease
Cardiovascular diseases and cancer are the leading cause of morbidity and mortality globally. Cardiotoxicity from chemotherapeutic agents results in substantial morbidity and mortality in cancer survivors and patients with active cancer. Cardiotoxicity induced by 5-fluorouracil (5-FU) has been well established, yet its incidence, mechanisms, and manifestation remain poorly defined. Ischemia secondary to coronary artery vasospasm is thought to be the most frequent cardiotoxic effect of 5-FU. The available evidence of 5-FU-induced epicardial coronary artery spasm and coronary microvascular dysfunction suggests that endothelial dysfunction or primary vascular smooth muscle dysfunction (an endothelial-independent mechanism) are the possible contributing factors to this form of cardiotoxicity. In patients with 5-FU-related coronary artery vasospasm, termination of chemotherapy and administration of nitrates or calcium channel blockers may improve ischemic symptoms. However, there are variable results after administration of nitrates or calcium channel blockers in patients treated with 5-FU presumed to have myocardial ischemia, suggesting mechanisms other than impaired vasodilatory response. 
  • 440
  • 22 Apr 2022
Topic Review
Vasopressor-Sparing and Patients with Shock
Vasopressor therapy is to restore organ perfusion so as to limit the risk of multiple organ failure and death.
  • 954
  • 11 Nov 2021
Topic Review
Vasopressin-Related Possible Therapies in Autism
Autism spectrum disorder (ASD) is rather common, presenting with prevalent early problems in social communication and accompanied by repetitive behavior. There is no cure for ASD, and there is currently no medication to treat it. The medications are prescribed mainly to treat self-injury, inability to focus, anxiety and depression (SSRIs), aggression (alpha-2 adrenergic agonist, Clonidine) and hyperactivity (dopamine and noradrenaline stimulant methylphenidate, Ritalin). Strategies to treat the core symptoms of ASD are directed to correct synaptic dysfunctions, abnormalities in central VP, OT and serotonin neurotransmission, and neuroinflammation. 
  • 344
  • 14 Dec 2023
Topic Review
Vasopressin in Sepsis and Other Shock States
Septic shock is defined by the need for vasopressors to correct hypotension and lactic acidosis secondary to infection, with a high mortality rate. The Surviving Sepsis Campaign guidelines recommend vasopressin as a second-line vasopressor, added to norepinephrine. 
  • 342
  • 07 Nov 2023
Topic Review
Vasoactive Intestinal Peptide Family Members in Diabetic Keratopathy
Diabetic keratopathy (DK) is a common ocular complication of diabetes, characterized by alteration of the normal wound-healing mechanism, reduction of epithelial hemidesmosomes, disruption of the basement membrane, impaired barrier function, reduced corneal sensitivity, corneal ulcers, and corneal edema.
  • 137
  • 28 Feb 2024
Topic Review
Vascularization of the Thyroid Gland
The thyroid gland is a richly vascularized endocrine gland. It is an uneven organ located in a median position in the antero-lower region of the neck, between the fifth cervical vertebra and the first thoracic vertebra.
  • 940
  • 29 Jan 2022
Topic Review
Vascular Smooth Muscle Cells Biomechanics
Cardiovascular diseases are one of the leading causes of global death in developing countries. More than 80% of cardiovascular disease-associated mortality is attributable to atherosclerosis, a chronic inflammatory disease of the vessel wall. During the development of atherosclerosis and other cardiovascular diseases, vascular smooth muscle cells (SMCs) continuously shift from a contractile state towards other phenotypes that differ substantially from differentiated SMCs.
  • 649
  • 22 Sep 2021
Topic Review
Vascular Permeability in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a disease that causes scarring and fibrotic transformation of the lung parenchyma, resulting in the progressive loss of respiratory function and, often, death. An increasing body of literature shows that pulmonary vascular permeability may play a big role in the pathogenesis of this condition. There is a search for therapeutic targets to try and modulate this vascular permeability in fibrotic lungs. One such class of targets that shows great promise is sphingolipids.
  • 308
  • 02 Aug 2023
Topic Review
Vascular Endothelium in Cardiovascular Diseases
The vascular endothelium plays a vital role during embryogenesis and aging and is a cell monolayer that lines the blood vessels. The immune system recognizes the endothelium as its own. Therefore, an abnormality of the endothelium exposes the tissues to the immune system and provokes inflammation and vascular diseases such as atherosclerosis. Its secretory role allows it to release vasoconstrictors and vasorelaxants as well as cardio-modulatory factors that maintain the proper functioning of the circulatory system. The sealing of the monolayer provided by adhesion molecules plays an important role in cardiovascular physiology and pathology.
  • 397
  • 01 Feb 2023
Topic Review
Vascular Endothelial Growth Factors
Vascular endothelial growth factors (VEGFs) are primary regulators of blood and lymphatic vessels. Hemangiogenic VEGFs (VEGF-A, PlGF, and VEGF-B) target mostly blood vessels, while the lymphangiogenic VEGFs (VEGF-C and VEGF-D) target mostly lymphatic vessels. Blocking VEGF-A is used today to treat several types of cancer (“antiangiogenic therapy”). However, in other diseases, it would be beneficial to do the opposite, namely to increase the activity of VEGFs. For example, VEGF-A could generate new blood vessels to protect from heart disease, and VEGF-C could generate new lymphatics to counteract lymphedema. Clinical trials that tried to stimulate blood vessel growth in ischemic diseases have been disappointing so far, and the first clinical trials targeting the lymphatic vasculature have progressed to phase II. Antiangiogenic drugs targeting VEGF-A such as bevacizumab or aflibercept neutralize the growth factor directly. However, since VEGF-C and VEGF-D are produced as inactive precursors, novel drugs against the lymphangiogenic VEGFs could also target the enzymatic activation of VEGF-C and VEGF-D. Because of the delicate balance between too much and too little vascular growth, a detailed understanding of the activation of the VEGF-C and VEGF-D is needed before such concepts can be converted into safe and efficacious therapies.
  • 3.0K
  • 30 Mar 2021
  • Page
  • of
  • 1349
Featured Entry Collections
>>

Featured Books

>>
Encyclopedia of Social Sciences
Encyclopedia of COVID-19
Encyclopedia of Fungi
Encyclopedia of Digital Society, Industry 5.0 and Smart City
Video Production Service
Feedback